Reportlinker Adds Global Cardiovascular Disease Diagnostics Industry

Mar 21, 2011, 13:25 ET from Reportlinker

NEW YORK, March 21, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Cardiovascular Disease Diagnostics Industry

http://www.reportlinker.com/p087285/Global-Cardiovascular-Disease-Diagnostics-Industry.html

This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in US$ Million by the following product segments - Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 71 companies including many key and niche players worldwide such as AccuTech, LLC, Abbott Diagnostics, Alere Inc., Biosite, Inc., Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., biomerieux, Cambridge Heart, Inc., Cholestech Corp., GE HealthCare, Home Access Health Corporation, LifeSign LLC, Liposcience, Inc., Nanosphere, Inc., Ortho-Clinical Diagnostics, Inc., Philips Healthcare, Polymer Technology Systems, Inc., Response Biomedical Corp., Roche Diagnostics, Siemens Healthcare Diagnostics, Inc., St. Jude Medical, Inc., and EP MedSystems. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 3

Quantitative Techniques & Analytics 3

Product Definitions and Scope of Study 3

In Vitro Diagnostics 3

In Vivo Diagnostics 3

2. INDUSTRY OVERVIEW 5

Cardiovascular Diseases: The Undying Challenge 5

Table 1: Region-Wise Incidence and Prevalence of

Cardiovascular Diseases in 2006 6

Mounting Healthcare Costs - Calls for Early Diagnosis 6

Cardiovascular Disease Diagnostics: Playing a Pivotal Role in

Early Disease Detection 6

Developed Countries Dominate, Developing to be the Future

Growth Engine 7

Fast and Accurate Diagnosis - Reduce Unnecessary Healthcare Costs 7

POC Diagnostics Market Gains Momentum 8

Cardiac Markers - Making Diagnosis Easier and Quicker 8

Major Cardiac Markers and their Properties 9

What's New in POC Cardiac Markers Space? 9

Leading Players 10

List of Point of Care Cardiac Marker Testing Products 10

3. IN-VIVO DIAGNOSTICS 11

Table 2: Global In-vivo Cardiovascular Disease Diagnostics

Market by Region: 2010 (includes corresponding Graph/Chart) 11

Novel Imaging Techniques Boost In vivo Diagnostics Market 11

Non-Invasive Procedure Hogs the Limelight for Cardiovascular

Treatment 12

Cardiology Diagnostic Imaging 12

New Technologies Bring Diagnostics Closer to Patients 12

Trends Cited in the Imaging Technologies Market 13

CT Scanners 13

MRI 14

Move Towards Efficient Patient Data Management 14

4. IN-VITRO DIAGNOSTICS 15

A Quick Insight into the Global In-vitro Diagnostics Market 15

Growth Trends 15

Developed Countries Drive In-Vitro Diagnostics (IVD) Market 15

Table 3: Leading In-Vitro Diagnostics Markets Worldwide

(2007): Percentage Breakdown for North America, Europe,

Japan, and Others (includes corresponding Graph/Chart) 16

Established Players Dominate the Fragmented Market 16

Table 4: Leading Players in the Global In-Vitro Diagnostics

Market (2009): Percentage Breakdown of Value Sales for Roche

Diagnostics, Abbott Diagnostics, Ortho/ LifeScan,

Bayer/Siemens, Beckman Coulter, BD, Dade Behring, bioMerieux

and Others (includes corresponding Graph/Chart) 16

Point-of-Care In-Vitro Testing on the Roll 17

Table 5: Global In vitro Diagnostics Market by Type of Test

(2007): Percentage Breakdown for Central Lab Testing,

Point-of-Care Testing, and Molecular Testing (includes

corresponding Graph/Chart) 17

A Specific Focus on Global Cardiovascular In-Vitro Diagnostics

Market 17

Market Analysis 18

Table 6: World Cardiovascular In-vitro Diagnostics Market:

2010 (includes corresponding Graph/Chart) 18

Aging Population Drives Home Testing Market 18

Cholesterol and Other Cardiovascular Test Kits Offered by

Leading Companies 19

Development of Home Cholesterol Testing Kits 19

Table 7: Global Cholesterol Point-of-Care Rapid Tests Market

(2009): Market Shares of Leading Players by Value Sales for

Inverness Medical, Roche, Abaxis, and Others (includes

corresponding Graph/Chart) 19

Strong Demand for Risk Assessment Markers 19

Advancements in Alternate-Site Coagulation Monitoring 20

5. CVD - CAUSE AND RISK FACTORS 21

CVD - Global Facts 21

Table 8: CVD Death Rates (per 100,000 population) Among Men

(Aged 35-74 years) by Select Country: 2007 (includes

corresponding Graph/Chart) 21

Table 9: CVD Death Rates (per 100,000 population) Among Women

(Aged 35-74 years) by Select Country: 2007 (includes

corresponding Graph/Chart) 22

Atherosclerosis - Leading Cause for CVD 22

Risk Factors 22

Irreversible Risk Factors 22

Increasing age 22

Sex (gender) 23

Heredity (including Race) 23

Risk Factors that can be controlled 23

Tobacco Smoke 23

High Blood Cholesterol 23

LDL Cholesterol 24

HDL Cholesterol 24

Triglyceride levels 24

Hypercholesterolemia - Conditions Associated with

Cholesterol Level 25

High Blood Pressure 25

BP - Leading Cause of Cardiovascular Disease in Young Adults 26

Physical Inactivity 26

Obesity and Overweight 26

Diabetes Mellitus 26

Cardiovascular Disease and Homocysteine Levels 26

Measures for Reducing Cardiovascular Diseases 27

6. CARDIOVASCULAR DISEASE AND CONDITIONS 28

Angina Pectoris 28

Arrhythmias 28

Sudden Cardiac Death (SCD) 28

Stroke 28

Congestive Heart Failure 29

Heart Failure Classification as per the NYHA and ACC/AHA 29

Table 10: Prevalence Rates of Congestive Heart Failure in

Select Countries (per 10,000) (includes corresponding

Graph/Chart) 30

Cardiovascular Disease Involving Transplant Patients 30

7. DIAGNOSTIC TESTS FOR CARDIOVASCULAR DISEASES 31

In-Vitro Cardiovascular Diagnostics 31

Cholesterol Testing 31

Use of Markers 31

Creatine Kinase MB 31

Troponin T and Troponin I 32

C-Reactive Protein 32

Plasminogen Activator Inhibitor-1 33

D-Dimer 33

Thrombus Precursor Protein 33

Other Cardiac Markers 33

Increasing Popularity of Risk Assessment Markers 33

A Step Forward in Cardiovascular Risk Assessment 34

In Vivo Diagnostic Tests 34

Computed Imaging / Tomography 34

Electron Beam Computed Tomography (EBCT) 34

Appropriate Conditions for EBCT Diagnosis 35

Cardiac Positron Emission Tomography (PET) 35

Digital Cardiac Angiography/ Digital Subtraction Angiography 36

Magnetic Resonance Imaging (MRI) 36

Single Photon Emission Computed Tomography (SPECT) 37

Echocardiography 37

Different Types of Echo-techniques 37

M-mode (Motion mode, One-dimensional) 37

Two-Dimensional (Cross-sectional) 38

Stress Echocardiogram (Stress Echo) 38

Transesophageal Echocardiogram (TEE) 38

Risks 38

Ultrasound Tests 38

Doppler Ultrasound 38

Intravascular Ultrasound 39

Working 39

Comparative Facts Related to Definitive Diagnosis of

Cardiovascular Disease 39

Nuclear Cardiology Tests 40

Applications 40

Types of Nuclear Cardiology Tests 40

Myocardial Perfusion Imaging 40

Applications 41

Risks 41

Ventricular Function Test 41

Testing Cardiac Stress 42

Cardio Vascular Disease Diagnostics Tests in the Pipeline 42

Aderis MRE-0470 42

CardioMEMS Novel Technology 42

Technology Platform 42

8. PRODUCT LAUNCHES AND DEVELOPMENTS 43

Cardiac Science Launches Microvolt T-Wave Alternans Module 43

Cleveland HeartLab to Extend Test Menu 43

St. Jude Medical Introduces EnSite Derexi Module 43

NorDiag Unveils NorDiags Arrow Instrument 44

Biosense Webster Launches CARTO® 3 System 44

McKesson Unveils New Variant of Horizon Cardiology

Cardiovascular Information System 44

Correlagen Launches CardioGeneScan Test 44

Royal Philips Electronics to Launch PageWriter TC50 Cardiograph 45

Philips Introduces Xcelera R3.1 45

St. Jude Medical Launches Medical Devices for Heart Rhythms

Disorders 45

TomTec and Medis Launches Cardiac Imaging and Analysis Product 46

Royal Philips Electronics Launches PageWriter TC70 46

Philips Healthcare to Introduce CX50 CompactXtreme 47

Royal Philips Electronics Introduces Xcelera R2.2 47

Toshiba America to Launch AplioTM Artida 47

9. PRODUCT LAUNCHES AND DEVELOPMENTS IN THE RECENT PAST - A

PERSPECTIVE BUILDER 49

Philips Rolls Out 256-slice CT scanner, Brilliance iCT Scanner 49

Royal Philips Launches Live 3D Transesophageal Echocardiogram

Probe 49

GE Healthcare Launches Vivid e Ultrasound Systems 49

Cardionetics Launches ECG Monitor for 24-Hour Real-Time

Cardiac Diagnosis 49

Siemens Launches Imaging Release for the ACUSON Sequoia Platform 50

GE Healthcare Launches Version 2.0 of Centricity Cardiology

CA1000 50

GE Healthcare Introduces New Capabilities to CardioSoft

Diagnostic Software 50

GE Healthcare's Lightspeed VCT Offers Imaging at 70% Lower

Exposure 50

Roche Diagnostics Launches cobas h 232 Portable Cardiac Marker

System (Outside US) 51

Royal Philips Launches New Imaging Tool for Complex Cardiac

Arrhythmias 51

Siemens Medical Introduces syngo® US, New Echocardiography

Solution. 51

Dade Behring Introduces CardioPhase® hsCRP Test for Multiple

Testing Platforms. 51

Shimadzu Launches Two Models in Angiographic Imaging 52

Omron Healthcare Introduces Non Invasive Vascular Profiling

System 52

Abbott Launches XIENCE V, New Coronary Stent System 52

Siemens Medical Introduces Acuson AcuNav 8F, an Advanced

Ultrasound Catheter 52

BioMerieux Introduces High Performance VIDAS Troponin I Ultra 53

Siemens Launches Acuson X300 Ultrasound Platform 53

Siemens Releases Web-Enabled CT 53

GE Introduces Latest Electrocardiograph Device, MAC 3500 54

GE Emphasizes on the Striking Features of New Vivid 7

Dimension '06 54

GE Launches Latest Innova Digital Flat Panel Biplane Imaging

Devices 54

Medtronic Introduces Latest Range of Implantable Cardiac

Defibrillators 55

Philips Introduces Web Based Cardiac Tools 55

Siemens Showcases Solutions for Cardiac Problems Through

Molecular Imaging 55

Siemens Presents Advancements in Echocardiography 55

Siemens Debuts syngo BEAT 56

Siemens Combines syngo® Dynamics with Soarian® for

Cardiovascular EPR 56

GE Healthcare Unveils CardIQ Fusion 56

GE Introduces Discovery VCT 56

GE Unveils Dynamic VUE 56

GE Launches CardIQ Xpress 57

GE Presents the Ventri for Cardiac Imaging 57

GE Introduces High Definition Magnetic Resonance System 57

Dade Behring Unveils CardioPhase(R) hsCRP Test 57

Siemens Launches Encompass III on C512 Ultrasound Platform 57

Siemens Launches Four New CT Clinical Engines 58

Omron Launches HEM-9000AI Cardiovascular Diagnostic Tool 58

Corgenix Introduces Predictive Cardiovascular Diagnostic Kit,

AtherOx™ 58

Philips Introduces HD11 XE Cardiology Ultrasound System 58

Siemens Introduces Biplane FD Cardiology System 59

Siemens Introduces Syngo Circulation Software for CT Tomography 59

Siemens Introduces SOMATOM Definition for Cardiac Imaging 59

Dade Behring Unveils Homocysteine Test on BN (TM) Systems 59

Roche Unveils Cardiac pro-BNP Test 59

Philips Introduces HD11 XE 60

Corgenix Unveils AtherOx(TM) 60

GE Healthcare Unveils Breakthrough Imaging Technology 60

Philips Launches Products to Detect Heart Problems 60

Philips Unveils Computed Tomography and EP Planning package 61

Philips Widens Magnetic Resonance Portfolio 61

New Cardiac Monitoring Products from Philips 61

Siemens Launches Image-Arena 61

Siemens Announces New Procam-Calculator Combined with CT

Examination 61

Siemens Medical Solutions Launches Axiom Artis dTA 62

GE Healthcare Unveils Vivid i 62

GE Healthcare Presents Fully Integrated 4D Cardiovascular

Ultrasound System 63

GE Healthcare Debuts New Imaging System 63

New Discovery PET/CT Systems from GE Healthcare 63

SonoSite Presents SonoCalc IMT Software 63

Dade Behring Introduces High Sensitivity Troponin I Assay 64

Biosite Unveils New Diagnostic Test 64

MDS Diagnostic Services Unveils New Test to Prevent Heart Disease 64

diaDexus Develops PLAC Test 65

Siemens Introduces New Nuclear Cardiology Imaging System 65

Roche Diagnostics Receives U.S. Clearance and European CE Mark 65

Camtronics Unveils Cardiovascular Screening Software 66

Mayo Pioneers New Enzyme-Based Cardiovascular Risk Assessment

Test 66

10. RECENT INDUSTRY ACTIVITY 67

Inverness Changes Name to Alere 67

Miraculins Acquires PreMD's PREVU(i) Skin Cholesterol Test Assets 67

Kardia Health Systems Partners with TomTec Imaging Systems 67

TriLink and Biofortuna Ink Licensing Agreement 67

Corgenix Enters into a Strategic Alliance with ELITech 68

VaxGen to Merge with diaDexus 68

St. Jude Medical to Take Over LightLab Imaging 68

GE Healthcare and CardioDx Enter into Strategic Alliance 69

bioMerieux and Knome Ink Strategic Partnership Agreement 69

Merge Healthcare Acquires AMICAS 69

Diamedix and Nova Ink Distribution Agreement 70

Inverness Acquires Standard Diagnostics 70

Quidel Acquires Diagnostic Hybrids 70

bioMerieux Acquires Meikang Biotech 70

Aurora Health Care Partners with Celera 71

Mediscience Technology Corporation Acquires SensiVida Medical

Systems 71

Volcano Acquires Axsun Technologies 71

Thermo Fisher Takes Over B.R.A.H.M.S. 71

SonoSite Acquires CardioDynamics International 72

IntriCon Snaps Up Datrix 72

ST. Jude Medical Receives US FDA and European Approval for

EnSite Velocity™ Cardiac Mapping System 72

Roche Inks Agreement with Response Biomedical 72

Dynatek Dalta Scientific Inks Agreement with State Food and

Drug Administration 73

Amic Inks Licensing Deal with Roche Diagnostics 73

TRICARE Includes Atherotech's VAP® Test 73

PreMD Receives NSE Letter from US FDA for POC Skin Cholesterol

Test 74

Amic Gains License for Roche's Cardiac Marker 74

diaDexus and Fisher HealthCare Sign Agreement 74

Inverness Inks Distribution Agreement with PrognostiX 75

GE Healthcare Enters into Collaboration with Boston Scientific 75

St. Jude Medical Acquires EP MedSystems 75

11. INDUSTRY ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER 76

Inverness Takes Over Biosite 76

Siemens Medical Acquires Dade Behring 76

Inverness Medical Innovations Acquires Cholestech 76

Acrongenomics, Pearson and Molecular Enter into Joint Venture 77

Cholestech Teams Up with Onsite Health Diagnostics 77

Lipomics to Collaborate with Agilent Technologies to Develop

Diagnostic Tests. 77

Transgenomic and Fiuotecnica Renew Collaboration Agreement 78

Alteon and BioRap Technologies Enter into an Agreement 78

IM Medical Acquires New Technology for Detecting

Cardiovascular Diseases 78

Medtronic Establishes New Business Entity 78

Siemens Medical Acquires Bayer Healthcare's Diagnostics Unit 79

Inverness Medical Innovations Completes Acquisition of HemoSense 79

Spacelabs Acquires Ferraris' Cardiac Unit 79

Global Immune Takes over Primedical International 80

Siemens Acquires Diagnostics Products 80

Cholestech and Life Line Enter into Collaboration 80

LipoScience Signs an Agreement with ARUP 80

Philips Acquires Witt Biomedical 80

CardioDynamics Enters into an OEM Agreement with Shenzhen Mindray 81

Biosense Enters into Strategic Partnership with Siemens

Medical Solutions 81

Dade Behring Approved the Use of FSAP Antibodies by American

Diagnostica 81

Abbott Receives Non-exclusive Sublicense for Diagnostic Use of

PIGF 81

Nanogen Acquires Spectral's Cardiac Test Division 82

Varian Enters into Alliance with LipoScience to Jointly

Develop NMR System 82

Cardiac Services Professionals Establish eCardio Diagnostics 82

Response Biomedical Wins Nonexclusive License Rights for NT-

proBNP and Troponin T 83

Biomerieux gains Nonexclusive License for NT-proBNP 83

Philips and PMI Ink an Agreement for Outpatient Facility 83

LipoScience Enters into an Agreement with LabCorp 83

Abbott and Cleveland Clinic to Co-develop Myeloperoxidase

Cardiac Test 83

Abbott Receives 510(k) Clearance from FDA for Myoglobin Test 84

FDA Clears Additional Claim for Biosite's Triage (R) BNP Test 84

Biosite Inks an Agreement with University of Mainz 84

Dade Behring Receives FDA Clearance for Advanced D-Dimer Assay 84

Nanogen Acquires SYN•X Pharma 84

GE Takes Over Amersham Plc 85

St. Jude Medical Acquires Irvine Biomedical and Epicor 85

SonoSite Snaps Up SonoMetric 85

CardioDynamics Acquires Vermed 85

Philips and EP MedSystems Announce an Alliance Involving

Electrophysiology Solutions 85

Toshiba and ViTAL Enters into an Alliance with Johns Hopkins

University School of Medicine 85

Response Biomedical Collaborates with Shionogi 86

Terumo Signs Agreement with Spencer Technologies 86

Spectral Diagnostics Announces Agreement with NGC Medical 86

Philips Signs Agreement with Fletcher Allen Health Care 86

Spectral Diagnostics Enters into an Agreement with Cardinal

Health 86

Siemens Signs Agreement with MediGuide 86

Biosite Enters into Agreement with DMI BioSciences 87

Cambridge Heart Enters into Agreement with Del Mar Reynolds 87

Cholestech Enters into an Agreement with Itamar Medical 87

Siemens Enters into a Contract with HiPGraphics 87

Abbott Announces US Clearance for Axis-Shield's BNP Test for

Use on AxSYM 88

Cholestech Announces FDA 510(k) Approval for hs-CRP Test 88

Dade Behring Bags FDA Clearance NT-proBNP Test 88

Dade Behring Receives FDA Clearance for N High Sensitivity CRP

Assay 88

EP-4 Computerized Cardiac Stimulator Bags FDA Approval 88

Biosite Adds two new offices 88

Bayer Diagnostics Enhances BNP Assay Offering Globally 89

EP MedSystems Garners CE Approval for ALERT Deflectable CS

Catheter in Europe 89

Cambridge Heart Inc. and Quinton Cardiology Systems Renew Pact 89

EPIX and Schering AG Extends Collaboration Agreement 90

Siemens Ultrasound and TomTec Imaging Systems Announces Agreement 90

FIT Biotech Plc Acquires Xenerate Ab to Develop Innovative

Cardiovascular Devices 90

Beckman Coulter Enters into Agreement with Biosite 90

Dade Behring Garners Non-exclusive Rights for a Key Cardiac

Marker 91

Bracco Diagnostics Inc., Joins Hand with Eastern Isotopes Inc

to Develop CardioGen-82® 91

New Lab Test from diaDexus Receives FDA Clearance 91

Hypertension Diagnostics Receives SDA Approval in China 91

12. FOCUS ON SELECT GLOBAL PLAYERS 92

AccuTech, LLC (USA) 92

Abbott Diagnostics (USA) 92

Alere Inc. (USA) 92

Biosite, Inc. (USA) 94

Ani Biotech Oy (Finland) 94

Axis-Shield PoC (UK) 94

Beckman Coulter, Inc. (USA) 95

biomerieux (France) 95

Cambridge Heart, Inc. (USA) 95

Cholestech Corp. (USA) 96

GE HealthCare (UK) 96

Home Access Health Corporation (USA) 97

LifeSign LLC (USA) 97

Liposcience, Inc. (USA) 97

Nanosphere, Inc. (USA) 98

Ortho-Clinical Diagnostics, Inc. (USA) 98

Philips Healthcare (USA) 98

Polymer Technology Systems, Inc. (USA) 99

Response Biomedical Corp. (Canada) 99

Roche Diagnostics (Switzerland) 100

Siemens Healthcare Diagnostics, Inc. (USA) 100

St. Jude Medical, Inc. (USA) 101

EP MedSystems (USA) 101

13. GLOBAL MARKET PERSPECTIVE 102

Table 11: World Recent Past, Current & Future Market Analysis

for Cardiovascular Disease Diagnostics by Geographic Region -

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Middle East and Latin America Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2007 through

2015 (includes corresponding Graph/Chart) 102

Table 12: World Historic Review for Cardiovascular Disease

Diagnostics by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Middle East, and Latin America

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 103

Table 13: World 11-Year Perspective for Cardiovascular Disease

Diagnostics by Geographic Region - Percentage Breakdown of

Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Middle East and Latin America Markets for

Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 104

Table 14: World Recent Past, Current & Future Market Analysis

for Cardiovascular In Vitro Diagnostics by Geographic Region -

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Middle East and Latin America Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2007 through

2015 (includes corresponding Graph/Chart) 105

Table 15: World Historic Review for Cardiovascular In Vitro

Diagnostics by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Middle East and Latin America

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 106

Table 16: World 11-Year Perspective for Cardiovascular In

Vitro Diagnostics by Geographic Region - Percentage Breakdown

of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Middle East and Latin America Markets for

Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 107

Table 17: World Recent Past, Current & Future Market Analysis

for Cardiovascular In Vivo Diagnostics by Geographic Region -

US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Middle East and Latin America Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2007 through

2015 (includes corresponding Graph/Chart) 108

Table 18: World Historic Review for Cardiovascular In Vivo

Diagnostics by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific (excluding Japan), Middle East and Latin America

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 109

Table 19: World 11-Year Perspective for Cardiovascular In Vivo

Diagnostics by Geographic Region - Percentage Breakdown of

Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific

(excluding Japan), Middle East and Latin America Markets for

Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 110

14. THE UNITED STATES 111

A.Market Analysis 111

Trends and Issues 111

Innovations Drive the Usage of Cardiovascular Monitoring

Systems 111

Cholesterol POCT Market: An Overview 111

Table 20: US Cholesterol Point-of-Care Testing (2009):

Market Shares of Leading Players by Value Sales for

Inverness Medical, Polymer Technology Systems, and Roche

Diagnostics (includes corresponding Graph/Chart) 112

Increasing Cardiovascular Ailments Drive Sales of Home Test

Devices 112

CHF Biomarkers to Spearhead the US market 112

Table 21: US AMI (Acute Myocardial Infarction) Diagnostics

Market: Market Share by Revenue held by Major Players

(Dade Behring, Beckman Coulter, Bayer Diagnostics, and

Others) in 2006 (includes corresponding Graph/Chart) 113

Table 22: US CHF (Congestive Heart Failure) Diagnostics

Market: Market Share by Revenue held by Major Players

(Dade Behring, Beckman Coulter, Bayer Diagnostics, and

Others) in 2006 (includes corresponding Graph/Chart) 113

Cardiovascular Disease Prevalence in the US 113

Key Statistics on Cardiovascular Diseases 114

Mortality Statistics 114

Table 23: Prevalence of Cardiovascular Disease in the US

(2004): A Historic Review (includes corresponding

Graph/Chart) 115

Table 24: Percentage Breakdown of Deaths from

Cardiovascular Diseases in the US (2004): A Historic Review

(includes corresponding Graph/Chart) 115

Table 25: Prevalence of Cardiovascular Diseases among

Americans by Age (Age 20 and Older) and Sex (2004): A

Historic Review (includes corresponding Graph/Chart) 116

Table 26: A Factoid of CHD and MI (In Million) in the US

(2003): A Historic Review 116

Startling facts related to Stroke in US 116

Table 27: A Factoid of Stroke (In Million) in the US

(2003): A Historic Review 117

Incidence of Coronary Heart Disease 117

AHA Statistics for Coronary Heart Disease 117

Mortality rates of CHD 118

Table 28: Annual Number of Americans Having Diagnosed

Heart Attack by Age and Sex (2004) (includes corresponding

Graph/Chart) 118

Table 29: Prevalence of CHD by Age and Sex (2004) (In %

population) (includes corresponding Graph/Chart) 119

Arrhythmias 119

CAD Diagnostics 119

PVD Diagnostics 120

Medicare Reimbursement Set for CPT Code 83704 120

Competitive Glance 120

Point-of-Care (POC) Diagnostics Market in the US 120

Table 30: Leading Players in the US POC Cardiac Market

(2004) - Percentage Breakdown by Value Sales for Biosite,

Dade Behring, Spectral Diagnostics, Roche and Others

(includes corresponding Graph/Chart) 121

B.Market Analytics 121

Table 31: US Recent Past, Current & Future Analysis for

Cardiovascular Disease Diagnostics by Product Segment - In

Vitro Diagnostics and In Vivo Diagnostics Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 121

Table 32: US Historic Review for Cardiovascular Disease

Diagnostics by Product Segment - In Vitro Diagnostics and In

Vivo Diagnostics Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 122

Table 33: US 11-Year Perspective for Cardiovascular Disease

Diagnostics by Product Segment - Percentage Breakdown of

Dollar Sales for In Vitro Diagnostics and In Vivo

Diagnostics Markets for 2005, 2010 & 2015 122

15. CANADA 123

A.Market Analysis 123

Cardiovascular Disease Facts 123

B.Market Analytics 123

Table 34: Canadian Recent Past, Current & Future Analysis

for Cardiovascular Disease Diagnostics by Product Segment -

In Vitro Diagnostics and In Vivo Diagnostics Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 123

Table 35: Canadian Historic Review for Cardiovascular

Disease Diagnostics by Product Segment - In Vitro

Diagnostics and In Vivo Diagnostics Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2000 through 2006 (includes corresponding Graph/Chart) 124

Table 36: Canadian 11-Year Perspective for Cardiovascular

Disease Diagnostics by Product Segment - Percentage

Breakdown of Dollar Sales for In Vitro Diagnostics and In

Vivo Diagnostics Markets for 2005, 2010 & 2015 124

16. JAPAN 125

Market Analysis 125

Table 37: Japanese Recent Past, Current & Future Analysis

for Cardiovascular Disease Diagnostics by Product Segment -

In Vitro Diagnostics and In Vivo Diagnostics Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 125

Table 38: Japanese Historic Review for Cardiovascular

Disease Diagnostics by Product Segment - In Vitro

Diagnostics and In Vivo Diagnostics Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2000 through 2006 (includes corresponding Graph/Chart) 126

Table 39: Japanese 11-Year Perspective for Cardiovascular

Disease Diagnostics by Product Segment - Percentage

Breakdown of Dollar Sales for In Vitro Diagnostics and In

Vivo Diagnostics Markets for 2005, 2010 & 2015 126

17. EUROPE 127

A.Market Analysis 127

In Vivo Diagnostics - Major Segment in CVD Diagnostics Market 127

Germany - The Largest European Market 127

Cardiovascular Disease - Mortality Statistics 127

Table 40: Leading Cause of Death Among Men in Europe

(2007): Percentage Breakdown for Cardiovascular Diseases,

Poisoning and Injuries, Respiratory Disease, Cancer, and

Others (includes corresponding Graph/Chart) 128

Table 41: Leading Cause of Death Among Women in Europe

(2007): Percentage Breakdown for Cardiovascular Diseases,

Poisoning and Injuries, Respiratory Disease, Cancer, and

Others (includes corresponding Graph/Chart) 128

Cardiovascular Disease - Risk Factor Profile 128

The Cardiovascular Disease Cost Burden 129

B.Market Analytics 129

Table 42: European Recent Past, Current & Future Analysis

for Cardiovascular Disease Diagnostics by Geographic Region

- France, Germany, Italy, UK, Spain, Russia & Rest of Europe

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 129

Table 43: European Historic Review for Cardiovascular

Disease Diagnostics by Geographic Region - France, Germany,

Italy, UK, Spain, Russia & Rest of Europe Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2006 (includes corresponding

Graph/Chart) 130

Table 44: European Recent Past, Current & Future Analysis

for Cardiovascular Disease Diagnostics by Product Segment -

In Vitro Diagnostics and In Vivo Diagnostics Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 131

Table 45: European Historic Review for Cardiovascular

Disease Diagnostics by Product Segment - In Vitro

Diagnostics and In Vivo Diagnostics Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2000 through 2006 (includes corresponding Graph/Chart) 132

Table 46: European 11-Year Perspective for Cardiovascular

Diagnostics by Geographic Region - Percentage Breakdown of

Dollar Sales for France, Germany, Italy, UK, Spain, Russia &

Rest of Europe Markets for Years 2000, 2007 & 2010 (includes

corresponding Graph/Chart) 133

Table 47: European 11-Year Perspective for Cardiovascular

Disease Diagnostics by Product Segment - Percentage

Breakdown of Dollar Sales for In Vitro Diagnostics and In

Vivo Diagnostics Markets for 2005, 2010 & 2015 133

17a. FRANCE 134

Market Analysis 134

Table 48: French Recent Past, Current & Future Analysis for

Cardiovascular Disease Diagnostics by Product Segment - In

Vitro Diagnostics and In Vivo Diagnostics Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 134

Table 49: French Historic Review for Cardiovascular Disease

Diagnostics by Product Segment - In Vitro Diagnostics and In

Vivo Diagnostics Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 135

Table 50: French 11-Year Perspective for Cardiovascular

Disease Diagnostics by Product Segment - Percentage

Breakdown of Dollar Sales for In Vitro Diagnostics and In

Vivo Diagnostics Markets for 2005, 2010 & 2015 135

17b. GERMANY 136

Market Analysis 136

Table 51: German Recent Past, Current & Future Analysis for

Cardiovascular Disease Diagnostics by Product Segment - In

Vitro Diagnostics and In Vivo Diagnostics Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 136

Table 52: German Historic Review for Cardiovascular Disease

Diagnostics by Product Segment - In Vitro Diagnostics and In

Vivo Diagnostics Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 137

Table 53: German 11-Year Perspective for Cardiovascular

Disease Diagnostics by Product Segment - Percentage

Breakdown of Dollar Sales for In Vitro Diagnostics and In

Vivo Diagnostics Markets for 2005, 2010 & 2015 137

17c. ITALY 138

Market Analysis 138

Table 54: Italian Recent Past, Current & Future Analysis for

Cardiovascular Disease Diagnostics by Product Segment - In

Vitro Diagnostics and In Vivo Diagnostics Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 138

Table 55: Italian Historic Review for Cardiovascular Disease

Diagnostics by Product Segment - In Vitro Diagnostics and In

Vivo Diagnostics Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 139

Table 56: Italian 11-Year Perspective for Cardiovascular

Disease Diagnostics by Product Segment - Percentage

Breakdown of Dollar Sales for In Vitro Diagnostics and In

Vivo Diagnostics Markets for 2005, 2010 & 2015 139

17d.THE UNITED KINGDOM 140

A.Market Analysis 140

UK Cardiovascular Diseases Fact Sheet 140

B.Market Analytics 141

Table 57: UK Recent Past, Current & Future Analysis for

Cardiovascular Disease Diagnostics by Product Segment - In

Vitro Diagnostics and In Vivo Diagnostics Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 141

Table 58: UK Historic Review for Cardiovascular Disease

Diagnostics by Product Segment - In Vitro Diagnostics and In

Vivo Diagnostics Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 142

Table 59: UK 11-Year Perspective for Cardiovascular Disease

Diagnostics by Product Segment - Percentage Breakdown of

Dollar Sales for In Vitro Diagnostics and In Vivo

Diagnostics Markets for 2005, 2010 & 2015 142

17e. SPAIN 143

Market Analysis 143

Table 60: Spanish Recent Past, Current & Future Analysis for

Cardiovascular Disease Diagnostics by Product Segment - In

Vitro Diagnostics and In Vivo Diagnostics Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 143

Table 61: Spanish Historic Review for Cardiovascular Disease

Diagnostics by Product Segment - In Vitro Diagnostics and In

Vivo Diagnostics Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 144

Table 62: Spanish 11-Year Perspective for Cardiovascular

Disease Diagnostics by Product Segment - Percentage

Breakdown of Dollar Sales for In Vitro Diagnostics and In

Vivo Diagnostics Markets for 2005, 2010 & 2015 144

17f.RUSSIA 145

A.Market Analysis 145

Major Players 145

B.Market Analytics 146

Table 63: Russian Recent Past, Current & Future Analysis for

Cardiovascular Disease Diagnostics by Product Segment - In

Vitro Diagnostics and In Vivo Diagnostics Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 146

Table 64: Russian Historic Review for Cardiovascular Disease

Diagnostics by Product Segment - In Vitro Diagnostics and In

Vivo Diagnostics Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 147

Table 65: Russian 11-Year Perspective for Cardiovascular

Disease Diagnostics by Product Segment - Percentage

Breakdown of Dollar Sales for In Vitro Diagnostics and In

Vivo Diagnostics Markets for 2005, 2010 & 2015 147

17g. REST OF EUROPE 148

Market Analysis 148

Table 66: Rest of Europe Market for Cardiovascular Disease

Diagnostics - Recent Past, Current & Future Market Analysis

by Product Segment for In Vitro Diagnostics and In Vivo

Diagnostics Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 148

Table 67: Rest of Europe Historic Review for Cardiovascular

Disease Diagnostics by Product Segment - In Vitro

Diagnostics and In Vivo Diagnostics Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2000 through 2006 (includes corresponding Graph/Chart) 149

Table 68: Rest of Europe 11-Year Perspective for

Cardiovascular Disease Diagnostics by Product Segment -

Percentage Breakdown of Dollar Sales for In Vitro

Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 &

2015 149

18. ASIA PACIFIC 150

A.Market Analysis 150

Cardiovascular Market in Asia-Pacific 150

China 150

Healthcare Expenditure to Grow Considerably by 2015 150

In vitro Diagnostics Market Poised for Strong Growth 151

Domestic Manufacturers Pose a Threat for Overseas IVD

Manufacturers 151

Leading Players 151

Cardiovascular Disease Patients Overview 151

Treatment Providers and Hospitals Overview 152

Hospitals 152

Table 69: Cardiovascular Special Treatment Hospitals in

China: 1991-2011(In numbers) (includes corresponding

Graph/Chart) 152

Chinese Cardiovascular Disease Treatment as a Part of

Overall Health Care Industry 152

Table 70: Cardiovascular Disease Treatment in China:

1991-2006 (includes corresponding Graph/Chart) 153

B.Market Analytics 153

Table 71: Asia-Pacific Market for Cardiovascular Disease

Diagnostics - Recent Past, Current & Future Market Analysis

by Product Segment for In Vitro Diagnostics and In Vivo

Diagnostics Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 153

Table 72: Asia-Pacific Historic Review for Cardiovascular

Disease Diagnostics by Product Segment - In Vitro

Diagnostics and In Vivo Diagnostics Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2000 through 2006 (includes corresponding Graph/Chart) 154

Table 73: Asia-Pacific 11-Year Perspective for

Cardiovascular Disease Diagnostics by Product Segment -

Percentage Breakdown of Dollar Sales for In Vitro

Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 &

2015 154

19. THE MIDDLE EAST 155

Market Analysis 155

Table 74: The Middle East Market for Cardiovascular Disease

Diagnostics - Recent Past, Current & Future Market Analysis

by Product Segment for In Vitro Diagnostics and In Vivo

Diagnostics Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2000 through 2010 (includes

corresponding Graph/Chart) 155

Table 75: The Middle East Historic Review for Cardiovascular

Disease Diagnostics by Product Segment - In Vitro

Diagnostics and In Vivo Diagnostics Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2000 through 2006 (includes corresponding Graph/Chart) 156

Table 76: The Middle East 11-Year Perspective for

Cardiovascular Disease Diagnostics by Product Segment -

Percentage Breakdown of Dollar Sales for In Vitro

Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 &

2015 156

20. LATIN AMERICA 157

A.Market Analysis 157

Brazil: A Growing Market for IVD 157

Table 77: Brazilian IVD Market by Segment (2009):

Percentage Share Breakdown for Immunoassay, Hormone,

Microbiology, Biochemistry, Hematology, Molecular

Diagnostics, Cardiac markers, Hemostasis, and Cytology

(includes corresponding Graph/Chart) 157

B.Market Analytics 158

Table 78: Latin American Market for Cardiovascular Disease

Diagnostics - Recent Past, Current & Future Market Analysis

by Product Segment for In Vitro Diagnostics and In Vivo

Diagnostics Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2007 through 2015 (includes

corresponding Graph/Chart) 158

Table 79: Latin American Historic Review for Cardiovascular

Disease Diagnostics by Product Segment - In Vitro

Diagnostics and In Vivo Diagnostics Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2000 through 2006 (includes corresponding Graph/Chart) 159

Table 80: Latin American 11-Year Perspective for

Cardiovascular Disease Diagnostics by Product Segment -

Percentage Breakdown of Dollar Sales for In Vitro

Diagnostics and In Vivo Diagnostics Markets for 2000, 2010 &

2015 159

COMPETITIVE LANDSCAPE

Total Companies Profiled: 71 (including Divisions/Subsidiaries - 82)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 57

Canada 3

Japan 4

Europe 15

France 1

Germany 1

The United Kingdom 5

Italy 3

Rest of Europe 5

Asia-Pacific (Excluding Japan) 1

Middle-East 2

------------------------------------------

To order this report:

: Global Cardiovascular Disease Diagnostics Industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com